Home > Browse Issues > Vol.38 No.9
Establishment of Human Hepatocellular Carcinoma Cell MHCC97H Xenografts in BALB/c Nude Mice and Evaluation of Sorafenib in MHCC97H Xenografts
Yang Lu, Wu Yanhua*
School of Life Sciences, Fudan University, Shanghai 200438, China
Abstract: Sorafenib， the inhibitor of multiple tyrosine kinase including vascular endothelial growth factor receptor (VEGFR) and B-Raf， can effectively prolong the survival time of patients with advanced liver cancer.Our study successfully established human hepatocellular carcinoma cell MHCC97H subcutaneous and orthotopic xenograft models in BALB/c nude mice， and further evaluated the therapeutic effect of sorafenib on the 2 xenograft models. Our results showed that MHCC97H cells grew well after subcutaneously transplanted into BALB/c nude mice. Sorafenib in 30 mg/kg per os (p.o.) daily significantly inhibited tumor growth. Moreover， MHCC97H cells could also form orthotopic xenografts in the liver of BALB/c nude mice. Sorafenib in 30 mg/kg p.o. daily significantly reduced the AFP level in serum and suppressed tumor growth in mice liver. In conclusion， MHCC97H is an ideal liver cancer cell line in establishment of subcutaneous and orthotopic xenografts models. Sorafenib showed significant anti-tumor effect on the 2 xenograft models.
CN
EN